A CEO’s View on the IPO Window

Home/Financial/A CEO’s View on the IPO Window

A CEO’s View on the IPO Window

Ron Leuty of the San Francisco Business Times has a great interview feature with William Newell, CEO of Sutro Biopharma, about the company’s big deal with EMD Serono, other developments, and whispers of an IPO.

The intro:

“Sutro Biopharma Inc.’s “armed antibody” technology — aimed at creating the next generation of antibody-drug conjugates — recently nabbed a potential $298 million deal with Merck KGaA subsidiary EMD Serono.

The collaboration will net Sutro an upfront payment, which it did not disclose, and puts the company’s technology dead-center of EMD Serono’s program in cancer-fighting antibody-drug conjugates, or ADCs.

Sutro, which has been whispered as a potential IPO candidate, will receive payments for completing certain research, development and regulatory milestones, plus potential royalties.”

Full article/interview

September 26th, 2014|
X